EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 3.0

Clinical Benefits of Denosumab vs Zoledronate in Postmenopausal Women Previously Treated with Alendronate: A Two-Year Retrospective Study

Ziyuan Wang, Yazhao Mei, Li Shen, Jiemei Gu, Na Ren, Ya Wang, Zhenlin Zhang, Chun Wang

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s533224 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Ziyuan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shang…. Hauptthemen laut MEDLINE: Alendronate, Denosumab, Osteoporosis, Postmenopausal, Bone Density Conservation Agents. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlendronateDenosumabOsteoporosis, PostmenopausalBone Density Conservation AgentsZoledronic AcidOsteoporotic FracturesHumansFemaleRetrospective StudiesAgedBone DensityMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

denosumabnew-onset fracturetransitioned therapyzoledronate

Substanzen

AlendronateDenosumabBone Density Conservation AgentsZoledronic Acid

Autor:innen und Institutionen

  • Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republ…
  • Clinical Research Center, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

Zitieren

APA

Wang, Z., Mei, Y., Shen, L., Gu, J., Ren, N., Wang, Y., Zhang, Z., & Wang, C. (2025). Clinical Benefits of Denosumab vs Zoledronate in Postmenopausal Women Previously Treated with Alendronate: A Two-Year Retrospective Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s533224

Vancouver

Wang Z, Mei Y, Shen L, Gu J, Ren N, Wang Y, et al. Clinical Benefits of Denosumab vs Zoledronate in Postmenopausal Women Previously Treated with Alendronate: A Two-Year Retrospective Study. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s533224

BibTeX
@article{Wang2025,
  author = {Wang, Ziyuan and Mei, Yazhao and Shen, Li and Gu, Jiemei and Ren, Na and Wang, Ya and Zhang, Zhenlin and Wang, Chun},
  title = {Clinical Benefits of Denosumab vs Zoledronate in Postmenopausal Women Previously Treated with Alendronate: A Two-Year Retrospective Study},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s533224}
}
Kostenlos starten →